Sorrento Therapeutics Is Forming Pennant Pattern: Technical Levels To Watch
Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares moved higher Tuesday after the company announced Phase 2 Abivertinib clinical studies have completed patient enrollment in the U.S. and Brazil. The company is expecting top-line clinical data at the end of the third quarter.